CD22 bispecific CAR-T cells

CD22 bispecific CAR-T cells are a form of chimeric antigen receptor T-cell therapy engineered to target both the CD19 and CD22 antigens on B-cell malignancies. These therapies are designed to overcome resistance and relapse associated with single-antigen targeting (such as loss of CD19 expression after standard anti-CD19 CAR-T therapy). The dual targeting is achieved by incorporating two single-chain variable fragments (scFvs) specific for both antigens into a single or tandem construct. This approach has shown robust cytolytic activity against B-cell acute lymphoblastic leukemia (B-ALL) in preclinical models and early-phase clinical trials. Both autologous (patient-derived) and allogeneic (donor-derived) versions have been developed. Clinical studies indicate that these therapies can induce high rates of minimal residual disease-negative complete remission in relapsed/refractory B-ALL patients[1][2][3][5][8].

Other names

autologous bispecific CD19/CD22-targeted CAR-T cellstandem CD19- and CD22-directed CAR T-cellsTan-CAR T-cells